Amarin Corporation plc announced a series of appointments and leadership changes to its Board of Directors, including: Appointment of Erin Enright and Alfonso Chito Zulueta to the Board, effective immediately.
Ms. Enright and Mr. Zulueta will stand for re-election to the Board at the Company's 2022 Annual Meeting in June. Per Wold-Olsen, a director since January 2022, has been named Chairman of the Board, effective
immediately. Mr. Wold-Olsen will stand for re-election to the Board at the Company's 2022 Annual Meeting in June. As part of a planned retirement, David Stack, a director since 2012, and Joe Zakrzewski, a director
since 2010, will retire from the Board, effective at the close of the 2022 Annual Meeting. Mr. Wold-Olsen has been named Chair of the Remuneration Committee; Ms. Enright has been named Chair of the Audit Committee. Dr. Lars Ekman will remain a member of the Board. Ms. Enright brings more than 30 years of experience as a healthcare company executive and investor. She currently serves as Managing Partner at Prettybrook Partners, overseeing approximately 20 active investments in a variety of healthcare companies. Prior to her role at Prettybrook, Ms. Enright served as Chief Financial Officer of InfuSystem and as President of Lee Medical. Mr. Zulueta has more than three decades of experience in global strategic and leadership roles within large pharma, specifically with Eli Lilly and Company. At Eli Lilly, he held key senior positions including Vice President of Global Marketing, head of the Company's Asia Region, and most recently as President of International responsible for all geographies outside the United States and Canada.